Transaction · 0001995275-26-000018

Lennon David James

Lennon David James, CEO, reported a transaction classified as grant at Whitehawk Therapeutics, Inc. involving 193957.000000 shares for an estimated $0.00. Reported holdings after the transaction were 193957.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACEO
WHWKWhitehawk Therapeutics, Inc.
Trade date
Sep 15, 2026
Filing date
Sep 18, 2026
View on SEC Insider profile
Disclosed value$0Shares × reported price
Shares traded193k$0.00 per share
Holdings after193kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Filing warnings

Notes recorded with this filing
1 warning
amended filingThis transaction comes from an amended Form 4 filing.

WHWK price since this filing

Daily closing prices, with the filing date and available return windows
WHWK · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago -3.1%
Returns since7d -11.0%30d -31.2%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001995275-26-000018
Restricted Stock Units
Transaction date
Sep 15, 2026
Filed Sep 18, 2026, 08:41 PM · 3d delay
Shares
193,957 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
193,957 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Amended Filing Derivative Transaction Direct Ownership Large Holdings Increase
Filing-only score

-16 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
  • amended_filing-6 points

    is_amendment = true

    Amended filing: the original transaction may have been restated.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CHIEF EXECUTIVE OFFICER

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subjec…

  2. F2

    Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.

  3. F3

    The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's…

Amended filing · 0001995275-26-000018
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

WHWK